99久久精品免费观看国产,色网站免费,2021国内精品久久久久久影院,国产免费福利网站,欧美日韩国产精品综合,国内在线精品,国产三级日本三级日产三

CN / EN

News

Technoderma Medicines Receives FDA Approval for Its Atopic Dermatitis Drug IND

Release time: 2022-08-09 Article source: 特科羅

On Aug 9th, 2022, US Pacific Time, Technoderma Medicines (TDM), a drug discovery startup specialized in dermatology indications based at Jiaxing,China, announced that FDA approved the IND application of its novel experimental drug for the topical treatment of Atopic Dermatitis (AD) by issuing a STUDY MAY PROCEED letter on Aug 1st, 2022. Phase I clinical trials will be carried out in several clinical sites in the US.


TDM-180935, TDM’s experimental drug approved in the IND application, is the first one out of several preclinical candidates from the company’s small molecule JAK inhibitor discovery program to enter clinical phase. Based on kinase, cellular and functional assays, TDM-180935 is a JAK1/TYK2 dual inhibitor.


Preclinical MoA studies revealed that TDM-180935 can potently inhibit Th2 immune response characteristic for the initiating phase of AD pathogenesis, as well as Th1 and Th17 immune responses that play a role during the chronic phase, thereby efficiently blocking all major pathogenic pathways leading to AD. The drug demonstrated dose-dependent efficacy on three mouse models for AD and a good safety profile as indicated by GLP toxicology studies.

TDM-180935 is the company’s second IND approval by FDA. Previously, TDM-105795, a small molecule thyroid hormone receptor agonist for the topical treatment of Androgenetic Alopecia (AGA) has been approved for phase I clinical trials in April 2021. Phase I trials of TDM-105795 will be completed in Q4 2022 and phase II trials are scheduled to start in Dec 2022 or Jan 2023.

汶上县| 湖北省| 株洲县| 汝州市| 巫山县| 吴川市| 阜新| 丰县| 台山市| 普格县| 高淳县| 万州区| 卢氏县| 邹平县| 桃园市| 嘉义市| 遂川县| 凤山市| 镇原县| 宁河县| 牡丹江市| 环江| 普洱| 杨浦区| 铁岭县| 岱山县| 彭泽县| 静乐县| 大姚县| 庆云县| 扶绥县| 泗阳县| 清丰县| 平顶山市| 满洲里市| 资源县| 马山县| 铅山县| 云和县| 公主岭市| 海阳市|